56results about How to "Diagnosis helps" patented technology

The invention relates to detection of genotypes, in particular to a primer and a probe for detecting relative fusion genes of leukemia and a kit of the primer and the probe. The kit can qualitatively detect quantity of BCR-ABL, AML1-ETO and PML-RARa of the relative fusion genes of the leukemia in human marrow specimens so as to instruct clinical diagnosis and pharmacy of the leukemia.

The invention provides a biomarker for diagnosing white matter lesion and application of the biomarker. The biomarker is ceramide (m18: 1 (4E)/24: 1 (15Z)) (Cer (m18: 1 (4E)/24: 1 (15Z))). According to the present invention, the biological marker ceramide (m18: 1 (4E)/24: 1 (15Z)) is combined with cholesterol-alpha-D-glucoside (Cholesteryl-alpha-D-glucoside), and is combined with 6Z, 9Z, 20-eicosatrienoic acid (6Z, 9Z, 20-Henecosatriene), ephedrine A (Cannflavin A), cucurbitacine E (Cucurbitacine E), cholesteryl ester 22: 6 (22: 6 Cholesteryl ester) or ceramide (d18: 0/24: 1 (15Z)) (Cer (d18: 0/24: 1 (15Z))) so as to determine whether the white matter lesion exists or not. The biomarker for diagnosing the white matter lesion is used for preparing a detection reagent for diagnosing the white matter lesion, and is beneficial for diagnosing whether the white matter lesion tends to exist or not and preventing the white matter lesion in advance.

The invention belongs to disease detection kit, and concretely relates to a kit for auxiliary diagnosis of Kawasaki disease by using miRNA as a biological label. The nucleic acid label is hsa-miR-223-3p, and the kit includes a primer subjected to a real-time quantitative polymerase chain reaction (RT-qPCR) for hsa-miR-223-3p. The kit can combine blood routine examination, high-sensitivity C reactive protein, erythrocyte sedimentation rate and cardiac ultrasonography, and is conducive to auxiliary diagnosis of Kawasaki disease and prediction damage of coronary artery.

The invention provides a biomarker for diagnosing white matter lesion and application thereof. The biomarker is ceramide (d18: 0/24: 1 (15Z)) (Cer (d18: 0/24: 1 (15Z))). According to the present invention, the biomarker ceramide (d18: 0/24: 1 (15Z)) is combined with cholesterol-alpha-D-glucoside (Cholesteryl-alpha-D-glucoside), and is combined with 6Z, 9Z, 20-eicosatrienoic acid (6Z, 9Z, 20-Henecosatriene), ephedrine A (Cannflavanin A), cucurbitacine E (Cucurbitacine E) or cholesteryl ester 22: 6 (22: 6 Cholesteryl ester) so as to determine whether the white matter lesion exists or not; the biomarker for diagnosing the white matter lesion is used for preparing a detection reagent for diagnosing the white matter lesion, and is beneficial for diagnosing whether the white matter lesion tends to exist or not and preventing the white matter lesion in advance.

The invention relates to an overheating fault diagnosis method of a transformer. The method comprises steps of calculating basic probability distribution functions of all kinds of faults on the evidence of codeless four ratios and characteristic gas by use of a posterior probability SVM; and then according to evidence theory definition, calculating fusion results of all kinds of the results under combined effects of multi-evidence bodies for belief functions of different evidence bodies. A probability estimation module is introduced in a 'one versus one' multiclass SVM by use of a pair-wise coupling algorithm, so defects of limitations on following data processing imposed by hard decision output when a traditional SVM is solving multiclass problems are overcome and an SVM probability output problem is effectively solved. According to the invention, by fully using redundant and complementation information of chromatographic data and electric test data and applying the D-S evidence theory, correction and reliability of comprehensive diagnosis results based on multi-default characteristics are greatly improved than the diagnosis based on single-default characteristics, which facilitates diagnosis of fault types of the transformer and has practical significance for formulation of maintenance strategies of the transformer.

The invention discloses a plasma exosome tRFs marker and an application thereof to breast cancer diagnosis. The marker is an exosome-derived tRF-Ser-AGA-018. The application of the marker includes theoperating steps: A building a unified specimen bank and a database, acquiring blood samples and tissue samples conforming to standards by standard operating procedures, and systematically collectingcomplete clinical data of included crowds; B analyzing tumor-induced exosome-derived tRFs disparity expression spectra in blood, selecting plasma samples of breast cancer cases and healthy persons, breast cancer tissues and para-carcinoma tissues, extracting exosomes, sequencing tRFs and tiRNA and screening out differentially expressed tRFs; C performing QRT-PCR (quantitative reverse transcriptionpolymerase chain reaction) analysis on the screened differentially expressed tRFs in large sample crowds. The tumor-induced exosome tRFs in the blood is a novel biomarker which realizes stability, minimal invasiveness and real-time monitoring, the sensitivity and the specificity of disease diagnosis are greatly improved, and successful development of the non-coding RNA (ribonucleic acid) biomarker is beneficial to breast cancer diagnosis.

The invention relates to a method for capturing the phthisic Proteome in biological samples by supporting the stroma with the bead and separating the bead from the samples by the magnetic separator without the centrifuged samples. Then conduct the protein fingerprinting by the analysis of mass spectrography. The reagent kit tests the sensibility and the specificity of the normal person with the tuberculosis by Double Blind Test, which are all 100percent, among which the deviant SAA A can be used as blood serum in vitro for testing the normal person, minor tuberculosis patient, recrudescent tuberculosis patient, severe tuberculosis patient and tuberculosis patient after effective treatment. The elevated deviant SAA A shows poor treatment effectiveness, severe tuberculosis and the recrudescent tuberculosis, thus being a protein fingerprinting group for early warning of the early detection on tuberculosis worsening and prediction on tuberculosis recrudescence. The method provided in the invention can be used as the reagent kit to distinguish the protein fingerprinting or mass spectrum mapping between the normal person and the tuberculosis patient. The method is correct, convenient and fast.

The invention relates to a proteome acquiring method which utilizes the method of the bead supporting stroma to capture the liver cancer protein group in the biology samples, and utilizes the magnetic separator to separate the bead and the sample without eccentric samples, and then utilizes the matter hidden method to analyze. The invention can be used in the protein fingerprint of the normal people and the liver cancer or the reagent box of the mass spectrum polypeptide atlas. The invention is accurate, convenient and quick.

The invention relates to a medical image processing method, a medical image processing device, a storage medium and computer equipment. According to the invention, during processing of a medical image, when it is detected that a first-level image structure contains abnormal signs, abnormal sign detection is continuously conducted on the second-level image structure contained in the first-level image structure, that is, abnormal sign detection is conducted on all the image structures according to the sequence from the high level to the low level, so that the abnormal detection can be comprehensive; and the target image structure containing the abnormal signs is determined based on the detection result, and then abnormal classification is performed through at least one classification model,so that the accuracy of the abnormal classification result can be enhanced, reliable abnormal category information can be obtained to support the doctor to perform further diagnosis, and the doctor can perform accurate diagnosis in the later period.

This invention relates to a protein dactylography for analysis of biological sample. This invention also relates to protein dactylography method for analyzing for the protein group got by retention chromatography. This method adopts mass spectroscopy to distinguish and detect protein group. The analysis data takes the form of bar code (protein dactylography) read by computer. This method can be used to the diagnosis of cell and clinic diseases, such as tumor with accuracy, convenience and quickness.

The invention provides a biomarker for diagnosing cerebral infarction and white matter lesion and application of the biomarker. The biomarker is an application of galactosylceramide in preparation of a detection reagent for diagnosing cerebral infarction and white matter lesions, and the biomarker galactosylceramide is combined with glucosylceramide, beta-allopietapentaol, platyclalene, 1, 3Z, 6Z, 9Z-nonane tetraene, p-cymene, oxalic acid, 3-(stearoyloxy)-4-(trimethyl ammonium) butyrate for diagnosing cerebral infarction and white matter lesions, so the risk of suffering from cerebral infarction and white matter lesion can be judged, and the cerebral infarction and white matter lesion can be prevented in advance.

This invention also relates to protein dactylography method for analyzing for the protein group got by retention chromatography. This method adopts mass spectroscopy to distinguish and detect protein group. The analysis data takes the form of bar code (protein dactylography) read by computer. This invention method is used to detect the protein fingerprint in the normal cell, restocarcinoma patient cell and rectal polyp patient cell.

The invention relates to in-vitro detection reagents for clinical diagnosis and in particular relates to a cancer urine detection reagent. The urine detection reagent is prepared from iodine, potassium iodide, mercury chloride, concentrated sulfuric acid and distilled water. After the test solution is dripped into the urine, the urine immediately develops color, precipitates of different colors are naturally downwards precipitated within 5-15 minutes, whether the detected patients are healthy patients or patients suffering from nephritis, benign tumors and malignant tumors can be judged by virtue of different colors developed by the solution and precipitates. According to the detection reagent disclosed by the invention, the defects in the prior art are overcome, and the detection reagent is a rapid metabolic disorder urine test reagent of a novel formula and has high stability, sensitivity and specificity and wide application range.

This invention relates to a protein fingerprinting using stranded chromatography catch and analysis proteins. The method identifies and detects proteins in mass spectrometry. Analysis of the data is obtained in the form of computer-readable bar code format (protein fingerprint). The invention method can be used to detect blood cells in patients with renal cell carcinoma and normal cell protein fingerprints. The method is accurate, fast and convenient.

The invention provides application of a biomarker phosphatidylinositol (22: 0/19: 0) in preparation of a detection reagent for diagnosing cerebral infarction of a white matter lesion patient. The risk of cerebral infarction of the white matter lesion patient is judged by combining the biomarker lipophosphatidylinositol (22: 0/19: 0) with glucosylceramide (d18: 0/24: 1 (15Z)), beta-hydroxyethyl ethanolamine, tomatidine, phosphatidylserine (22: 6/20: 1) or decanoyl carnitine. Cerebral infarction can be prevented in advance.

The standard substance kit is a standardization quality-controlled blood serum sampler packaged in tubule. Under -80 deg. C, the pooled serum is taken out and is diluted in U9 buffer solution in 1:2 mixing ratio; saving it at 25 deg. C. A quantification mass spectrographic analysis under the control of standardization quality-controlled O type blood serum is used for test.

This invention also relates to protein dactylography method for analyzing for the protein group got by retention chromatography. This method adopts mass spectroscopy to distinguish and detect protein group. The analysis data takes the form of bar code (protein dactylography) read by computer. This invention method can be used to detect protein fingerprint in the normal cell and cancer of stomach patient cell in the blood.

The invention relates to an albumen dactyloscopy analyzed by protein group. Utilizing mass spectrography to distinguish, the method discovers a new end-cut fiber albumen peptide A which can be used to test lymph node transfer of gastric cancer cells. The method is accurate, convenient and speed.

The invention discloses a transformer fault diagnosis method and system based on a neural network, and the method comprises the steps: taking a transformer fault diagnosis result as a target object, carrying out the coding of the target object, setting an initial cluster, and eliminating and updating a new group; selecting an error function calculated each time as a fitness function, initially calculating a fitness population of each population, selecting a new population and eliminating an old population; genetic operators are selected according to the probability, operator selection, crossover operators and mutation operators are carried out in sequence, and a fault diagnosis result is generated. According to the invention, intelligent diagnosis of the fault type and the fault degree of the transformer can be realized, diagnosis of the fault of the transformer is facilitated, and the method has an effective guiding effect on engineering practice.

This invention also relates to protein dactylography method for analyzing for the protein group got by retention chromatography. This method adopts mass spectroscopy to distinguish and detect protein group. The analysis data takes the form of bar code (protein dactylography) read by computer. This invention method can be used to detect protein fingerprint in the normal cell and cancer of stomach patient cell in the blood.